This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Allergan
Information provided by (Responsible Party):
Allergan Identifier:
First received: May 20, 2016
Last updated: July 18, 2017
Last verified: July 2017
This study will evaluate the safety, tolerability and efficacy of the oral administration of setipiprant tablets 1000 mg twice daily (BID) relative to placebo in 18 to 49 years old males with androgenetic alopecia (AGA).

Condition Intervention Phase
Alopecia Drug: setipiprant Drug: placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males

Resource links provided by NLM:

Further study details as provided by Allergan:

Primary Outcome Measures:
  • Change from Baseline in Target Area Hair Count (TAHC) within a 1 cm^2 Circular Area [ Time Frame: Baseline, Week 24 ]
  • Subject Self-Assessment (SSA) of the Change in Scalp Hair Growth using a 7-Point Scale [ Time Frame: Baseline, Week 24 ]

Estimated Enrollment: 163
Actual Study Start Date: June 29, 2016
Estimated Study Completion Date: August 30, 2018
Estimated Primary Completion Date: June 30, 2018 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Setipiprant
1000 mg setipiprant (two 500 mg tablets) twice daily (BID) at 12-hour intervals for 24 weeks.
Drug: setipiprant
Two 500 mg setipiprant tablets BID.
Other Name: KYTH-105
Placebo Comparator: Placebo
Two placebo tablets BID at 12-hour intervals for 24 weeks.
Drug: placebo
Two placebo tablets BID.


Ages Eligible for Study:   18 Years to 49 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Participant has androgenetic alopecia (AGA)
  • Participant agrees to maintain current hair care regimen, refraining from hair weaving, hair colorants or dyes and non-study hair growth products during the study.

Exclusion Criteria:

  • History of hair loss for reasons other than AGA
  • Scarring of the scalp or any condition or disease of the scalp, hair or hair shaft
  • Use of products within 6 months of study start used continuously for at least 1 month that could impact hair growth
  • Hair-weaving within 6 months
  • Use of hair colorants or dyes within 6 months.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT02781311

Contact: Clinical Trials Registry Team 1-877-277-8566

United States, Arkansas
Burke Pharmaceutical Research Recruiting
Hot Springs, Arkansas, United States, 71913
Petrus Center for Aesthetic Surgery & Hair Transplantation Recruiting
Little Rock, Arkansas, United States, 72205
United States, California
Therapeutics Clinical Research Recruiting
San Diego, California, United States, 92123
Radiant Research, Inc. Recruiting
Santa Rosa, California, United States, 95405
United States, Florida
Ameriderm Research Withdrawn
Ormond Beach, Florida, United States, 32174
United States, Illinois
DeNova Research Recruiting
Chicago, Illinois, United States, 60611
DuPage Medical Group Withdrawn
Naperville, Illinois, United States, 60563
United States, Kansas
Heartland Research Associates, LLC Recruiting
Wichita, Kansas, United States, 67207
United States, Michigan
Michigan Center for Skin Care Research Recruiting
Clinton, Michigan, United States, 48038
United States, Minnesota
Minnesota Clinical Study Center Recruiting
Fridley, Minnesota, United States, 55432
University of Minnesota Recruiting
Minneapolis, Minnesota, United States, 55455
United States, North Carolina
Wake Forest University Health Sciences Recruiting
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Cleveland Clinic Recruiting
Cleveland, Ohio, United States, 44195
United States, Oregon
NW Dermatology & Research Center Recruiting
Portland, Oregon, United States, 97210
Oregon Medical Research Center Recruiting
Portland, Oregon, United States, 97223
United States, Pennsylvania
Penn State Hershey Medical Center Recruiting
Hershey, Pennsylvania, United States, 17033
United States, South Carolina
Radiant Research, Inc. Recruiting
Greer, South Carolina, United States, 29650
United States, Texas
DermResearch, Inc Recruiting
Austin, Texas, United States, 78759
J&S Studies, Inc Withdrawn
College Station, Texas, United States, 77845
Suzzane Bruce and Associates P.A., The Center for Skin Research Recruiting
Katy, Texas, United States, 77494
United States, Virginia
The Education & Research Foundation Recruiting
Lynchburg, Virginia, United States, 24501
Sponsors and Collaborators
Study Director: Gurpreet Ahluwalia Allergan
  More Information

Additional Information:
Responsible Party: Allergan Identifier: NCT02781311     History of Changes
Other Study ID Numbers: 1922-201-002
Study First Received: May 20, 2016
Last Updated: July 18, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Alopecia Areata
Hair Diseases
Skin Diseases
Pathological Conditions, Anatomical processed this record on September 21, 2017